Christine Blank
Contributing Editor Christine Blank is a freelance writer based in Florida.
New drug indication could net more than $1 billion
FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion.
Breast cancer biosimilar shows equivalency to brand
Breast cancer biosimilar shows equivalency to brand
Two new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency.
Human trials of Zika vaccine underway
The Army has made significant progress on the Zika vaccine in just 10 months. Details here.
HIV vaccine could be nail in coffin for disease
A clinical study, recently begun in South Africa, is testing whether an experimental vaccine regimen safely prevents HIV infection.
Issues about biosimilar substitution
At a time when biosimilars are of strong interest to insurers and health care systems for cost control, physicians are not rushing to issue a blank check for their substitution. Details here.
Pharmacy prices vary widely for generic heart drugs
The prices of heart failure drugs at retail pharmacies vary widely, and uninsured patients may not be able to afford them, researchers have found.
FDA approves 2 injectable diabetes drugs
Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.
Novel drug reduces monthly migraine days
A global phase 3 study of erenumab (Amgen and Novartis) showed that the drug was able to prevent migraines headaches.
Multidrug-resistant HIV drug on the horizon
After a successful phase 3 study, a breakthrough therapy to treat multi-drug resistant (MDR) HIV-1 is expected to launch in the United States in 2017.
Bridging the online pharmacy knowledge gap
A majority of pharmacists don’t talk to patients about online pharmacies.


View Results